In the early stages, fatty liver may be asymptomatic, with most people unaware they have it. However, continued fat buildup ...

A European Medicines Agency committee, on Thursday, accepted the use of an artificial intelligence (AI) tool called AIM-NASH ...

EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...

Researchers identify the Asah1 gene as a promising target for novel therapies to treat nonalcoholic fatty liver disease ...

The liver is essential for digestion, metabolism, detoxification, and fluid regulation. While alcohol abuse is a known cause ...

One of these is non-alcoholic steatohepatitis, or NASH, the fatty liver disease that affects millions of people and which is poised to be one of pharma’s next big growth areas. Novartis ramped ...

Otherwise, it would lead to diseases like acute (sudden) hepatitis (inflammation), chronic (long duration) hepatitis, fatty ...

(NALD)(Shutterstock) According to him, NAFLD, if severe and progressing, can lead to an irreversible condition—liver cirrhosis, with non-alcoholic steatohepatitis (NASH) and liver fibrosis as ...

The MAESTRO-NASH OUTCOMES trial will further assess resmetirom's efficacy and safety. At 2 years, participants in the compensated MASH cirrhosis treatment arm of the MAESTRO-NAFLD-1 trial ...

The advent of artificial intelligence (AI) in healthcare is creating waves of innovation, transforming traditional medical practices. One of the ...

The new two-year data from MAESTRO-NAFLD-1 reinforce our confidence in the ongoing, fully enrolled MAESTRO-NASH OUTCOMES trial of Rezdiffra in patients with compensated MASH cirrhosis. If our ...